〔Abstract〕 Objective To screen Cuproptosis genes and characteristic genes for differential prognosis in acute myeloid leukemia(AML) and explore their prognosis in AML as well as their biological roles and correlations in the immune and tumor microenvironment. Methods AML clinical, transcriptome, genomic, and copy number data were downloaded from three major databases, TCGA, GEO, and UCSC, and Cuproptosis genes were collected from published studies. From the perspective of multiomics, the effects of Cuproptosis gene and characteristic gene on survival, immunity, tumor microenvironment, stem cell correlation and drug sensitivity were studied by various bioinformatics methods, meta-analysis and secondary typing. Results One Cuproptosis gene was identified as a differential prognostic gene in AML and five characteristic genes were identified as influencing the prognosis of AML patients by influencing Cuproptosis, and a prognostic model was established. The differential genes were mainly concentrated in mitochondrial activity, REDOX enzyme and energy metabolism. In terms of immunity, macrophage M0, neutrophils, activated memory CD4 T cells and Tregs were positively correlated with risk score, while macrophage M2, resting mast cells, immature CD4 T cells, helper follicular T cells and memory B cells were negatively correlated with risk score. In terms of tumor microenvironment, the immune cell score of the low-risk group was lower than that of the high-risk group, and in the total score, the tumor microenvironment score of the low-risk group was also lower than that of the high-risk group, indicating that the tumor purity of the high-risk group was lower than that of the low-risk group. However, there was no significant association between stem cells in the high-risk and low-risk groups, and a total of 14 drugs were found to be sensitive to treat AML. Conclusion Cuproptosis gene and characteristic gene are closely related to immune and tumor microenvironment in AML by constructing a prognostic model of AML.